Drug
Aln Rsv01
Aln Rsv01: highest development phase Phase 2, developed by Alnylam Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| ALN-RSV01 NCT00496821 | Phase 2 | Respiratory Syncytial Virus Infections |
Latest
No recent events.
Follow Aln Rsv01 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.